Cyberonics (CYBX) - FREE Research Report Verratti Mark who is VP Global Sales at Cyberonics sold 3,661 shares at $67.96 on Nov. 27, 2013. Following this transaction, the VP Global Sales owned 52,719 shares meaning that the stake was reduced by 6.49% with the 3,661 share transaction. The shares most recently traded at $69.36, up $1.40, or 2.03% since the insider transaction. Historical insider transactions for Cyberonics go as follows:
4-Week # shares sold: 10,161
12-Week # shares sold: 25,198
24-Week # shares sold: 60,288
The average volume for Cyberonics has been 208,500 shares per day over the past 30 days. Cyberonics has a market cap of $1.9 billion and is part of the health care sector and health services industry. Shares are up 31.49% year to date as of the close of trading on Wednesday. Cyberonics, Inc., together with its subsidiaries, engages in the design, development, marketing, and sale of implantable medical devices to hospitals and ambulatory surgery centers. The company has a P/E ratio of 40.6. Currently there are 6 analysts that rate Cyberonics a buy, no analysts rate it a sell, and 1 rates it a hold. Exclusive Offer: Get the latest Stock Analysis on CYBX - FREETheStreet Quant Ratings rates Cyberonics as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in net income, growth in earnings per share and solid stock price performance. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full Cyberonics Ratings Report from TheStreet Quant Ratings now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.